ProCE Banner Activity

Antibody‒Drug Conjugates Targeting TROP-2 in NSCLC: A Look to the Future


Downloadable slides capturing key information on TROP-2‒targeted antibody‒drug conjugates in NSCLC, including available efficacy and safety data, recommended supportive care strategies, and important ongoing clinical trials.

Released: July 25, 2023



Hossein Borghaei

Hossein Borghaei, MS, DO

Professor and Chief, Thoracic Medical Oncology
The Gloria and Edmund M. Dunn Chair in Thoracic Oncology
Department of Hematology and Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Rebecca S. Heist

Rebecca S. Heist, MD, MPH

Associate Professor of Medicine
Harvard Medical School
Medical Oncology
Massachusetts General Hospital
Boston, Massachusetts

Melissa L. Johnson

Melissa L. Johnson, MD

Director, Lung Cancer Research Program
Sarah Cannon Research Institute
Nashville, Tennessee

Benjamin Levy

Benjamin Levy, MD

Associate Professor
Johns Hopkins School of Medicine
Baltimore, Maryland

Stephen V. Liu

Stephen V. Liu, MD

Associate Professor of Medicine
Director, Thoracic Oncology
Head, Developmental Therapeutics
Georgetown University
Washington, DC

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by an educational grant from AstraZeneca, Daiichi Sankyo, Inc., and Gilead Sciences, Inc.


Daiichi Sankyo, Inc.

Gilead Sciences, Inc.